1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study : ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy
(
- Contribution to journal › Article
- 2023
-
Mark
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer : A subgroup analysis of the randomised clinical TITAN study
(
- Contribution to journal › Article
- 2022
-
Mark
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer : Results from the Prospective, International, Observational Prostate Cancer Registry
(
- Contribution to journal › Article
- 2021
-
Mark
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer : Data from the Prostate Cancer Registry
(
- Contribution to journal › Article
-
Mark
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer : Analysis of Pain and Fatigue in the Phase 3 TITAN Study
(
- Contribution to journal › Article
-
Mark
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer : Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
2021) In Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39(20). p.2294-2303(
- Contribution to journal › Article
- 2019
-
Mark
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN) : a randomised, placebo-controlled, phase 3 study
(
- Contribution to journal › Article
-
Mark
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
(
- Contribution to journal › Article
- 2016
-
Mark
Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer
(
- Contribution to journal › Article
- 2014
-
Mark
Enzalutamide in metastatic prostate cancer before chemotherapy
(
- Contribution to journal › Article